Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.
Parkinson's disease is the second most common neurodegenerative disorder, with aging as the primary risk factor; prevalence is expected to increase globally due to population aging. Current treatments manage symptoms rather than cure the disease, and management is complicated by multiple comorbidities in older adults; this review examines disease management strategies and emerging care models aimed at improving quality of life.
This multicenter study investigates the co-occurrence of functional movement disorders alongside Parkinson's disease diagnosis. The research provides descriptive clinical data on how these movement conditions present together, contributing to understanding of complex neurological presentations in affected populations.
A study of 4,600 Italian patients with Parkinson's disease or atypical parkinsonism identified 20 new carriers of the RAB32 p.Ser71Arg variant, which was associated with earlier disease onset (average 51 years) and good response to dopaminergic therapy. Carriers showed positive family history in 55.5% of cases, suggesting dominant inheritance patterns, with generally preserved cognitive function and mild psychiatric symptoms.
This expert consensus document provides evidence-based clinical guidance on screening, diagnosis, and treatment of gastrointestinal dysfunction in Parkinson disease, a common non-motor symptom that can precede motor symptoms and significantly impact quality of life. Recommendations are organized by anatomical segments (oral cavity, esophagus, stomach, small intestine, colon) based on a modified Delphi panel approach involving movement disorder neurologists and gastroenterologists.
Epidemiological and animal evidence indicates methamphetamine use significantly increases risk for Parkinson's disease and parkinsonism, potentially with earlier onset. Despite elevated prevalence in methamphetamine users, diagnosis is often missed due to under-detection, competing mortality risks, and confounding substance use patterns; clinicians should maintain vigilance for parkinsonian symptoms in this population.